A venture capital firm with offices in USA and Western Europe has multi-billion in assets under management and its mandate is to create companies with Seed and Series A funding (typically $50-100M), but it can also deploy smaller tickets into academic institutions for direct research funding. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.
The firm builds transformative life science companies by following the science, working with the best people, and investing for long term value creation. The firm is currently looking for companies in the Therapeutics space. The firm is most interested in companies developing novel biologics, however companies developing small molecules or biologic substitutes are also considered for investment. The firm is willing to invest in companies with a product in any phase of development, but it has a strong preference for discovery/preclinical assets.
The firm requires board seats in its portfolio companies. The firm also prefers to lead (or co-lead) any investment syndicates and looks to optimize the asset with additional resources beyond the typical venture investment mandate. The firm’s seasoned team of venture partners and entrepreneurs in-residence can also assume interim C-level positions, allowing recruiting flexibility as the company grows.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm With USA & Europe Offices Actively Engages in Company Creation and Seed to Series A Funding Towards Transformative Therapeutics
26 MayHot Investor Mandate: Innovation Arm of Large Health System Seeks to Invest in External Opportunities in Digital Health / Healthcare IT and Medical Devices Across the Globe
26 MayThe firm manages the investments in innovation for a large integrated delivery network health system with over 15 hospitals and 35,000 providers and employees. The firm is responsible for sourcing external innovation investments outside of the hospital system, and seeks early-stage co-investment opportunities led by quality lead venture firms, coupled with a strong emphasis on co-development opportunities with early-stage companies where the firm’s expertise in clinical, population health, health insurance services, and digital security can be most value-adding. The firm is open to global opportunities.
Currently, the firm is most interested in investments in digital health, HCIT, and process transformation opportunities, and will consider medical devices (predominantly of the wearables, monitoring types). The firm does not consider therapeutics companies at this time.
The firm is opportunistic, but examples of previous engagements have been in technologies targeting care administration/operations, cancer, cardiology, neuroscience and ALS, and even health-focused cybersecurity. As the firm heavily weights the ability to be an active co-development partner, it is open to the earliest stage digital health technologies, but companies who have yet to close a Seed round will be considered too early.
The firm does not have specific company or management team requirements. The Investment Office intends to leverage lead VC due diligence in its co-investment assessments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Digital Fatigue and the Future of Partnering
19 MayBy Rory McCann, Marketing Manager & Conference Producer, LSN
It will take decades to understand the full impact of the past couple years on the healthcare industry. These impacts range from public health adherence to treatments and even the rate of pharmaceutical development. However, beyond the obvious healthcare impacts are those that change how we work, interact, and communicate regularly. All these changes point to a need for connectivity, but also flexibility. Digital partnering has been a lifeline to many startups during the pandemic – building roads into networks of capital and licensing partners. However, as we move back into in-person partnering, the question remains is there a place for digital partnering in the future?
At Life Science Nation (LSN), we frequently source feedback from our clients and community. Surveys, one-on-one interviews, and conversations provide valuable insight into how market shifts have a real impact on the RESI network. We hear from the startup founder who is strapped for cash, looking for ways to connect with well-matched investors and strategic partners. For these clients, digital partnering is a low-cost alternative to in-person events. We also hear from busy investors, for whom the pandemic has increased productivity in that they can pack their days with meetings all from the convenience of home. We’ve also heard from entrepreneurs who would prefer to use their partnering budget for an optimum in-person option, as well as investors who have told us that it’s the quality of the in-person meeting that makes the deal, not the number of meetings in a day.
Digital fatigue is real, but it’s more complicated and nuanced than a single process or platform. One cause of fatigue is likely linked to the excess time and resources it takes to learn new systems and optimize them, not to mention the frustration that comes with knowing there aren’t other options available. We are now met with more options in the form of digital, in-person, and various forms of hybrid events. Going forward, it’s the goal of RESI to always offer attendees opportunities to connect with the partners who will join them along the way to their next milestone. This may take new forms but will prioritize both digital and in-person events to accommodate the unique needs of the early-stage ecosystem. As we look forward to our upcoming digital and in-person events, we hope to hear from our community how we can best support their efforts in continuing the important work they do to reshape the landscape of healthcare.
Digital RESI returns June 7-9 and may be the last chance before the summer breaks to connect with potential partners who are a fit for your product and stage of development. Participating in Digital RESI June could launch the second half of your 2022 global partnering campaign, with an in-person RESI September, Digital RESI November, and RESI JPM to round out the calendar. If you’d like an inside look at investors who are signed up who may be a fit for your needs or have questions about the digital format or your marketing collateral, contact us and we’d be happy to help!
|
Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
|
|||
|
International
|
East Coast (USA) & China
|
Midwest (USA)
& Canada |
West Coast (USA)
|
![]() |
![]() |
![]() |
![]() |
|
Greg Mannix
Vice President International Business Development Book a Meeting Email Me |
Candice He
VP, Business Development & Global Investment Strategist Book a Meeting Email Me |
Antoinette Lowre
Manager of Business Development Book a Meeting Email Me |
Alexander Vassallo
Manager of Business Development Book a Meeting Email Me |
The Global Entrepreneurial Classroom
19 MayBy Alexander Vassallo, Manager of Business Development West Coast (US), LSN
Launching and successfully growing a life science company is an extremely challenging endeavor, but if done successfully, can foster new paradigms of healthcare and lead to healthier lives for individuals around the globe. It is for this reason that Life Science Nation (LSN), the industry leader in connecting early-stage life science firms with capital investors and strategic partners, has developed a series of new educational courses, ranging from half a day to three days, for aspiring scientist-entrepreneurs and fundraising executives.
Launching and Funding Startups: Seed to Series B is a free half-day course designed to introduce early-stage life science executives to the tools and tips they will need to successfully launch a company and begin to interact with your target partners and investors. The course will cover several fundamental entrepreneurial concepts such as how to perform entrepreneurial due diligence, branding and messaging and the importance of telling a cogent company story through multiple modalities, and the 10 myths of fundraising. This course can be complemented by an optional afternoon session (bringing the course to a full day) where LSN staff will work directly with companies to help review their non-confidential materials, perform a competitive landscape analysis, and generate a global target list of investors.
Mapping the Landscape of Strategic Partners for Your Startup is a paid one-day course for fundraising executives who have launched an early-stage life science firm and will actively be seeking partners for capital (Seed to Series B), joint product collaboration, or licensing distribution deals. The course will cover a tactical to-do list for the early-stage entrepreneur and participants will be equipped with the skills and tools necessary to successfully undertake a global fundraising campaign. The course will finish with a Tales from the Road (TFTR) panel that will involve seasoned entrepreneurs in the LSN network sharing their experiences of their fundraising journeys and launching life science companies. The price of this course is $1,400 per company and includes two spots per company (one business and one science executive).
Preparing for Your Global Fundraising Roadshow is a paid two-day course that will cover an extensive dive into developing a professional set of marketing, non-confidential materials that the early-stage life science executive can bring to any investor meeting and partnering conference during their fundraising campaign: tagline, elevator pitch, executive summary, one-page data sheet, and pitch deck. Participants will also be taught how to research global investors, collaborators, and licensing partners who are a right fit for your company’s technology and stage of development and how to interact with your target partners. A third day of early-stage life science strategics can be added to the course (bringing it to a full three days) to further prepare participants for their fundraising journeys. Navigating the pitfalls that commonly catch first-time CEOs off-guard, creating a network of global alliances through social and business media, and mapping the competitive global landscape to elucidate the value of your startup are important themes that will be covered. The three-day version of the Preparing for Your Global Fundraising Roadshow course will conclude with a live Shark Tank to active investor judges. The price of the two-day course is $3,500, and the price of the three-day course is $4,500, with two spots per company for each course (one business and one science executive).
If you’re interested in learning more and participating in a course, please feel free to reach out to Alexander Vassallo at a.vassallo@lifesciencenation.com to schedule a call and explore the new range of LSN entrepreneurial education courses.
Crafting the Perfect Message
19 MayBy Karen Deyo, Director of Investor Research, Israel BD, LSN
You’ve registered for a partnering conference.
You’ve filled out a profile in the partnering system detailing who you are and what your company does.
You’ve researched the investors in attendance and built a list of targets to book meetings with.
You hit “Send Message” and freeze.
What do you say?
Partnering is an involved process with multiple steps that must be taken to ensure optimal results. These steps often require major time investment, and we forget that, even after the hours we’ve poured into the process, none of it matters without a compelling message to pique the interest of a potential partner.
Life Science Nation (LSN) has developed and consolidated the messaging process into easy steps:
- Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
- Company tagline (5-6 words explaining who you are and what you do)
- Elevator pitch (1-3 sentences describing the company and tech)
- Technology differentiation, product innovation, or market position
- Raise and milestone information
- Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
- Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development? What makes your people special?
- Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later. Even if the investor you’ve targeted is not a fit, this will make it easier for them to share your company with another.
It should go without saying that the perfect message is meaningless without a well-researched and formulated target list and marketing collateral at the ready. Think of the perfect message like how an athlete approaches the arena on game day. It’s the starting shot of a long and exciting process. It won’t replace the training and conditioning that got you to game day, but it’ll ensure you’re off with a competitive edge.
Partnering is open for Digital RESI, June 7-9 and there is still time to register! Contact us to see which investors are currently active in our partnering system who may be a fit for you.
|
Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
|
|||
|
International
|
East Coast (USA) & China
|
Midwest (USA)
& Canada |
West Coast (USA)
|
![]() |
![]() |
![]() |
![]() |
|
Greg Mannix
Vice President International Business Development Book a Meeting Email Me |
Candice He
VP, Business Development & Global Investment Strategist Book a Meeting Email Me |
Antoinette Lowre
Manager of Business Development Book a Meeting Email Me |
Alexander Vassallo
Manager of Business Development Book a Meeting Email Me |
Hot Investor Mandate: Family Office-Backed Financial Services Firm Actively Seeks New Investment Opportunities With Strong Interests in Therapeutics & Diagnostics
19 MayA newly established international investment banking and financial services firm with global offices is exclusively backed by a family office venture fund with over 20 years of investing in life sciences. The firm’s check sizes greatly vary depending on the deal and stage of development. The firm generally participates in rounds beyond seed stage. The firm actively seeks global opportunities.
The firm is most interested in therapeutics and diagnostics companies, but is also open to reviewing opportunities in medical devices, digital health, and research tools/equipment. Within therapeutics, the firm is excited about NCEs. In terms of disease area of indication, the firm has no particular preference and is opportunistic. The firm will expect to see a working prototype and a clear commercialization pathway established.
The firm places high importance on the management team and the story behind the company. While the firm is open to working with first-time or relatively inexperienced CEOs/management teams, BEP would like to see that the management team has relevant prior experience that will enable the company to successfully grow. The firm seeks to be a hands-on investor and can leverage their suite of services to help their portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA Fund of Large Asia-Based VC Firm Invests Up to $10M With Broad Interests in All Life Science Companies Based in North America and Europe
19 MayA US fund of a large Asia-based healthcare-focused venture capital firm seeks to make equity investments into early-stage life science companies. The sweet spot is seed to series B and the typical check size ranges from $5 – $10 million USD. The firm focuses on US, Canada or EU based companies. The firm prefers to co-invest or syndicate with other well-known investors.
The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics and Medical Technology. Digital Health and purely technology companies are less of interest.
The firm is open to working with entrepreneurs with all experience levels.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.











